Ultragenyx Pharmaceutical Inc [RARE] stock is trading at $24.11, down -1.07%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RARE shares have gain 6.97% over the last week, with a monthly amount drifted -33.40%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] stock has seen the most recent analyst activity on October 20, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $65. On May 28, 2025, William Blair initiated with an Outperform rating. Goldman upgraded its rating to a Buy and increased its price target to $67 on June 06, 2024. RBC Capital Mkts initiated its recommendation with an Outperform and recommended $77 as its price target on April 22, 2024. Wells Fargo started tracking with an Overweight rating for this stock on December 08, 2023, and assigned it a price target of $72.
Ultragenyx Pharmaceutical Inc [RARE] stock has fluctuated between $18.41 and $46.50 over the past year. Currently, Wall Street analysts expect the stock to reach $51.57 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $24.11 at the most recent close of the market. An investor can expect a potential return of 113.89% based on the average RARE price forecast.
Analyzing the RARE fundamentals
Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] reported sales of 630.60M for the trailing twelve months, which represents a growth of 14.65%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.86%, Pretax Profit Margin comes in at -0.91%, and Net Profit Margin reading is -0.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -4.14 and Total Capital is -0.64. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Ultragenyx Pharmaceutical Inc’s Current Ratio is 1.89. Further, the Quick Ratio stands at 1.74, while the Cash Ratio is 0.6. Considering the valuation of this stock, the price to sales ratio is 3.69, the price to book ratio is 253.42.
Transactions by insiders
Recent insider trading involved Horn Howard, Chief Financial Officer, that happened on Jan 02 ’26 when 3150.0 shares were sold. Officer, HOWARD HORN completed a deal on Jan 02 ’26 to buy 3150.0 shares. Meanwhile, SVP, Chief Accounting Officer Huizenga Theodore Alan sold 85.0 shares on Dec 29 ’25.
